Research Publications
Blood
Blood. (2021) July 22, Vol.138, (3), 246-258. “AID overexpression leads to aggressive murine CLL and non immunoglobulin mutations that mirror human neoplasms”
by i2medialab Trends in Immunology
Trends in Immunology. (2020). The Paradoxical Roles of Inflammation during PD-1 Blockade in Cancer.
by Ardan Pharma Clinical and Experimental Immunology
Clinical and Experimental Immunology. 2020. April 16; (200)155-162: “Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers”
by Ardan Pharma Cancer Cell
Cancer Cell. 2019 May 13;35(5):767-781 : “Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation”
by Ardan Pharma Blood
Blood. 2019. May 9;133(19):2056-2068: “Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia”.
by Ardan Pharma Blood
Blood. 2017 Aug 10;130(6):777-788.”S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression”.
by Ardan Pharma Press Release
Nature’s recent interview with our Founder & CSO, Dr. Marcelo Hill
ARDAN PHARMA is thrilled to announce its participation at the semifinalist stage of the 2021 Women’s Venture Competition – AIM-HI Accelerator.
by i2medialab ARDAN PHARMA is semifinalist in AIM-HI Accelerator Competition
ARDAN PHARMA is thrilled to announce its participation at the semifinalist stage of the 2021 Women’s Venture Competition – AIM-HI Accelerator.
by i2medialab Annual Investment Meeting
ARDAN PHARMA has been selected by Uruguay XXI-ANII, to attend to the Annual Investment Meeting (AIM), a World’s Leading Investment Platform , on its 10th edition next March 24-26 2020 at the Dubai World Trade Centre, Dubai, United Arab Emirates.
by Ardan Pharma Policies
Policies
ARDAN PHARMA maintains and discloses a written policy on financial conflict of interest which is consistent with 42 CFR. 50.
by i2medialab